Botox and Dermal Fillers in Orthodontics - A Review.

Botulinum toxin and derma fillers have made their way into dentistry in recent years for both cosmetic and medicinal purposes. They are here to stay, and with more and more intraoral applications, they are quickly becoming a standard element of dental treatment. They offer the most important, minimally invasive procedures at a cheap cost and with little to no downtime. Botox and derma fillers are used together for rejuvenation and esthetic operations nowadays. The mechanism of action and numerous uses of Botox and derma fillers in the maxillofacial areas, as well as their future implications in dentistry are discussed in this article. Copyright:

INTRODUCTION

In recent times, dentistry has focused on improvised breakthrough. The popularity of both botulinum toxin (BTX) and dermal fillers has developed promptly over the last few years because they give the regenerative and improving exquisite enhancements that were previously only possible with surgical procedure, but at a cheaper price and with minute to no healing time.[1] Botox and dermal fillers have been acknowledged by dentists and brought into clinical dentistry due to the encouraging outcomes acquired in facial esthetics and restoring a beauteous smile. The combination of a complete aggregate of teeth and a good facial esthetics creates a radiant smile.[2] With the goal of improving one's self-esteem, an increasing number of patients are focusing on minute details such as teeth and gums, as well as facial esthetics. The association between the gingiva lips and teeth defines the esthetic glimpse of a person, which was observed by Garber and Salama.[3]

Since the exploration of the demulcent utilization of BTX and dermal fillers, enhancing the facial esthetics has progressed in the last two decades.

BOTULINUM TOXIN

The most potent neurotoxin is BTX type A (BTXA). Following agitation of a toxin-releasing strain of Clostridium botulinum, which dissolves and releases the toxin into the culture, it is harvested from the culture medium. After that, the toxin is filtered, hastened, purified, and crystallized with ammonium sulfate. BTX-A should be kept refrigerated, but not frozen in this form. After reconstitution, BTX-A should be diluted with saline and utilized within 4 h.[4]

Mechanism of Action

The toxin is ingested and absorbed into the systemic circulation via the gastrointestinal tract. The toxin blocks the release of acetylcholine (ACH), a neurotransmitter involved in muscular contraction and activation of glandular secretion. The toxin causes a loss in tone in the muscle that has been administered. The toxin has no effect on some nerve terminals and allows the injected dystonic muscle to contract with less force. The hypertonic muscle's posture and function are improved as a result of this weakening. This weakens the muscle effectively for a duration of 3–4 months.[5]

Types

BTX is categorized into seven serogroups: A, B, C, D, E, F, and G. BTX is attainable in six different forms: BTA (Dysport®, Botox®, Xeomin®, PurTox®, and Prosigne®) and BTX-B (Neuroblocs®/Myobloc®). Unalike Dysport and Botox, which appear as a white powder that must be diluted, Myobloc is available in the form of a solution.[6] Because the element varies in each trademark, the dosage of BTX needed for the therapeutic approach of a state is determined by the brand or preparation. Table 1 lists many brands or preparations, as well as their physical qualities and indications.[7]

Table 1

Different brands or preparations, their physical properties, and indications

Toxin	Onabotulinum toxin A	Abobotulinum toxin-A	Incobotulinum toxin-A	Rimabotulinum toxin-B
Trade name	Botox® (Allergan Inc.)	Dysport®	Xeomin®	Myobloc®/Neurobloc®
Type	A	A	A	B
Molecular weight	900 kDa	500-900 kDa	150 kDa	700 kDa
Indication	Blepharospasm, cervical dystonia, primary axillary hyperhidrosis, urinary incontinence, chronic migraine, upper limb spasticity, cosmetic use	Blepharospasm, cervical dystonia, cosmetic use	Blepharospasm, cervical dystonia, cosmetic use	Cervical dystonia
Units/vial	100	500	50, 100	2500, 5000, 10,000
Storage prior to opening	2°C-8°C	2°C-8°C	2°C-8°C	2°C-8°C
Shelf life	36 months	24 months	36 months	24 months
Storage after opening	24 h/2°C–8°C	4 h/2°C–8°C	24 h/2°C–8°C	4 h/2°C–8°C

Application in Orthodontics

BTX is commonly utilized in the treatment of temporomandibular joint disorders and facial pain in the oral maxillofacial area, as well as for dental esthetics and therapeutics.

Temporomandibular disorders

In most temporomandibular disorder (TMD) cases, one or more muscle trigger areas are present. When these trigger areas are palpated, pain is transmitted along the muscle or neural tracks that emerge from them. Injections of aseptic saline and anesthetic drug are localized to these trigger locations. Short-term or long-term relief may be obtained by disrupting the trigger point. The therapeutic benefits of sterile saline or local anesthetic are limited because their effects last anywhere from a few minutes to a few days. The application of BTX for these trigger sites has proven to be quite effective; the muscular contraction strength is lowered, and the impact lasts for 3 months.

Facial pain

For TMD and facial pain cases, neurotoxins can be applied to various muscles of mastication, such as the temporalis, masseter, medial and lateral pterygoid muscles, and facial muscles such as orbicularis oculi, sternocleidomastoid, orbicularis oris, depressor anguli oris, mentalis, trapezius, splenius capitus, frontalis, procerus, and corrugator muscles.[8] Even if only one side of the temporalis and masseter muscles is affected, neurotoxins can be applied on both sides of the face.

Bruxism

Bruxism is a broad term that encompasses both teeth clenching and grinding. It causes TMD, headaches, and face pain, as well as the breakdown of good dentition and worsening of periodontal disease. In bruxism and TMD patients, toxin injections are delivered bilaterally into the masseter and temporalis muscles. Injecting the proper amount reduces the strength of mastication muscle contractions while also improving mastication and talking abilities. The neurotoxins can aid in the treatment of periodontal diseases by reducing facial pain and TMD symptoms and removing the bruxism factor.

Masseteric hypertrophy

Enlargement of the masseter muscles is known as masseteric hypertrophy. This frequently results in clenching and bruxism. Toxin injections into the belly of the masseter muscle are used to treat masseteric hypertrophy. This will result in a reduction in the intensity of masseter muscle contractions as well as a proximal reduction of the face; along with all botulinum therapies, repeated injections are needed in monthly intervals.[9]

Gummy smile

A gummy smile is a non-pathological condition in which the exposure of excessive gingival tissue while smiling causes esthetic disharmony. Hwang et al. proposed the Yonsei point in the middle of the triangle created by the zygomaticus minor, levator labii superioris alaeque nasi, and levator labii superioris muscles. At each injection site, a dose of 3 U is advised.[10]

Relapse after orthodontic treatment

Individuals with powerful muscular activity may have recessed activity after orthodontic treatment. During treatment, Botox can be administered to reduce the potency of muscles to contract, and thus, they can be moderately directed to a more normal action.

Trismus

Patients with TMD often have difficulty opening their mouths; BTA relaxes the neighboring masticatory muscles and reduces muscle inflammation, allowing the patients to open their mouths more easily. Injections of BTA into muscles of mastication had positive therapeutic consequences.[11]

Drug Interaction

d-Penicillamine, cyclosporine aminoquinolones, aminoglycosides, muscle relaxants, quinidine, and lincosamide are all drugs that affect the results of neurotoxin administration.[12]

Contraindications

Psychologically ill patients

Patients affected by a neuromuscular condition

Individuals with arrythmia and asthma

Those who are allergic to BTX and fillers

Pregnant and lactating women should avoid using BTA[13]

Complications

Because therapeutic doses of BTA are larger than those used for cosmetic purposes, complications are more common when it is used for therapeutic purposes. According to reports, roughly 7% of BTA patients develop resistance, prompting researchers to look into another type of BTX as an alternative treatment. Adverse effects such as palpitations, fever, tingling sensations, and nausea occur, which usually subside after 2 days. Pain, ecchymosis, and erythema near the injection site, facial asymmetry, ptosis, drooping of mouth, edema of lips, muscle weakness, dysphagia, aspiration, xerostomia, and hepatitis are the other complications.[14]

DERMAL FILLERS

Fillers are chemicals that can add volume to skin that has lost a significant amount of its natural volume. The source of dermal fillers and their potential to produce antigenicity are used to classify them.

Classification

Based on the characteristics of materials

Autologous: When a substance is obtained from the same person's body

Heterologous: When a substance is derived from multiple species

Alloplastic: When non-biological materials such as plastic, metal, or ceramic are employed

Based on biodegradability

Biodegradable products are those that can be broken down into non-hazardous substances.

Non-biodegradable: Substances that do not degrade in the natural environment

Based on the duration of the filler's action

Temporary: The impact lasts for less than 6 months.

Long-lasting effect: The effect might last anywhere from 6 months to 2 years.

Semi-permanent: The effect might last anywhere between 2 and 5 years.

Permanent: The effect does not disappear over time.[15]

Injection Planes

Unlike Botox, fillers should not be injected within the muscles. Because fat functions as a natural filler, injecting dermal fillers into the fat area is advisable. Dermal fillers should be ideally injected into the fat area. The fat area acts as a natural filler; hence, the fatty areas are suitable sites for injection. The fat on the face is divided into two planes: superficial and deep fat. The superficial plane runs parallel to the skin, while the deep plane runs parallel to the muscular layer. Injecting into the superficial fat at a depth of 3 mm ensures that the filler's impact lasts longer, and that the volume of filler deposited is lower.[16]

Hyaluronic Acid

Hyaluronic acid (HA), a key constituent of the extracellular matrix, is present within the skin, synovium, and eyes, among other places. De Maio has previously described the usefulness of HA fillers in altering muscle activity. He speculated that the HA fillers could affect muscular contraction mechanically by either aiding or inhibiting it.[17]

Collagen

Collagen is the skin's most vital structural component. Both bovine collagen and bioengineered human collagen dermal fillers are approved by the US Food and Drug Administration (FDA), and they are least painful for the patient upon injection, thus eliminating the necessity for anesthesia or nerve blocks.[18]

Calcium Hydroxylapatite (CaHA)

CaHA is an artificial microparticle encapsulated within a transporter gel and was licensed by the FDA in 2006 for the therapy of facial wrinkles and facial atrophy in human immunodeficiency virus (HIV) patients. CaHA makes about 30% of the gel, while the carrier gel makes up 70%. Injections lead to much more rapid visual improvement because of the durable accumulation of collagen around the microparticles, leading to a 15-month effect period.[19]

Poly-l-lactic Acid

Poly-l-lactic acid (PLLA) is an artificial, polymeric, recyclable, immunologically innocuous peptide polymer that stimulates fibroblasts to create more collagen, leading to increased facial volume. Soft tissue augmentation is achieved by inducing an inflammatory tissue response, which ends up in collagen deposition.[20]

Poly (methyl methacrylate)

Poly (methyl methacrylate) (PMMA) is formed of 80% bovine collagen and 20% PMMA microparticles. After the degradation of collagen over 3 months, the microspheres encased by a fine fibrous capsule are left. Silikon is administered in humans, which produces collagen around the silicone particles. Its application causes a lot of issues that are more difficult to address, because it is non-biodegradable.[21]

Applications in Dentistry

The fillers are used in the treatment of gummy smile, gingivectomy, periodontal and implant surgeries, and for enhancing lip and perioral volume.

Complications of Derma Fillers

Early side effects include erythema, edema, and bruising. Slow injection and small-volume delivery of local anesthetics minimize pain. Arnica, aloe vera, and naphthoquinone lotions are reported to assist with bruises. In circumstances where the patient has previously been sensitized, allergies might develop within hours. When an improper filler is injected superficially or within the wrong areas, lumps and bumps may develop.[22]

DISCUSSION

Onabotulinum toxin A was the first form of Botox to hit the market. The FDA recommended it as a cosmetic therapy for glabellar frown lines in 2002. The European Union granted the second formulation of onabotulinum toxin A, made in France, a license to be used for esthetic purposes in 2006, and the FDA approved it in 2009. Botox type A has become a catch-all phrase for all chemicals used in cosmetic procedures.[23] Collagen, HLA, CaHA, PLLA, and PMMA have all been approved by the FDA for facial injection.[24]

BTX and dermal fillers can be used to treat diagnostic and therapeutic issues. BTX and dermal fillers were also approved by the Michigan Board of Dentistry and the New Jersey State Board of Dentistry in 2014.[25]

Polo[26] administered 0.25 U of Botox to five patients who had increased gingival show caused by overactivity of upper lip elevator muscle. In patients with gummy smiles, Freund et al.[27] utilized dermal fillers in combination with Botox injections and found cosmetic and functional benefits. This combination was also used to treat lipstick lines, which were eliminated by modifying the contraction of orbicularis oris muscle. Daines and Williams[28] found that the black triangles were filled using interdental soft tissue fillers and Botox injections, and that the result lasted 3–4 months.

Freund et al.[29] administered BTXA into the temporalis and masseter muscles in TMD-related headaches and found that symptoms were relieved for 2–4 months. Erdal et al.[30] and Cersosimo et al.[31] discovered that BTX has anti-inflammatory properties. Hyperfunctional or spastic muscles are reduced by injecting into the masticatory musculature. Botox injections alleviated the terrible throbbing affliction due to trigeminal neuralgia of face, according to Elcio.[32]

CONCLUSION

Botox and derma fillers have made their way into dental field in recent years for cosmetic as well as therapeutic purposes in oral maxillofacial areas. They are here to put up, and with more intraoral applications, they are quickly becoming a staple of everyday dentistry treatment, with implications in restorative, cosmetic, periodontal, orthodontic, and prosthodontic treatments. For many common clinical scenarios, they give individuals the utmost substantial, accountable, meddling, cosmetic, and therapeutic effects accessible.

Financial support and sponsorship

Department of Orthodontics and Dentofacial Orthopaedics, D. Y. Patil School of Dentistry, Nerul, Navi Mumbai provided the financial support.

Conflicts of interest

There are no conflicts of interest.